Vargatef (Ovarian Cancer) Analysis and Forecats to 2020


#28298

33pages

GlobalData

$ 2000

In Stock


GlobalDatas pharmaceuticals report, Vargatef (Ovarian Cancer) - Analysis and Forecats to 2020 provides Vargatef sales forecasts for the US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

 

  • Therapy area profile including patient population for the US and EU5
  • Analysis and review of Vargatef including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Vargatef including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2017-2020 for Vargatef in the US and EU5


Reasons to buy

 

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

 

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Market Forecasts Report Guidance 8


3 Ovarian Cancer: Market Characterization 9
3.1 Ovarian Cancer Market 9
3.2 Ovarian Cancer Market Forecasts and CAGR 9
3.3 Drivers for Ovarian Cancer Market 10
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 12
3.3.4 Emergence of Targeted Drugs 12
3.3.5 Recurrence of Tumor 12
3.3.6 Low Initial Diagnosis Rate 12


4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 13


5 Vargatef 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.3.1 Phase I trial results Vargatef in Patients with Advanced Ovarian Cancer 16
5.3.2 Phase II trial results Vargatef as a Maintenance Treatment in Patients with Relapsed Ovarian Cancer 16
5.4 Factors Affecting Sales of Vargatef 17
5.4.1 Unmet Need 17
5.4.2 Poor Safety and Toxicity profile 17
5.4.3 Generic Competition 17
5.4.4 Vargatef Potential 17
5.4.5 Only Oral Triple Angiokinase Inhibitor 17
5.5 Drug Evaluation 18
5.5.1 Drug Risk Benefit Score 18
5.5.2 Intensity of Competition 19
5.6 Sales Forecasts of Vargatef 19
5.6.1 Target Patient Pool of Vargatef 19
5.6.2 Dosing 20
5.6.3 Market Penetration 20
5.6.4 Annual Cost of Therapy 20
5.6.5 Sales Projections of Vargatef 21


6 Ovarian Cancer Market: Appendix 29
6.1 Market Definitions 29
6.2 Abberiviations 29
6.3 Research Methodology 29
6.3.1 Coverage 29
6.3.2 Secondary Research 29
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 30
6.3.6 Net Annual Dosing 31
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 32
6.5 Disclaimer 32
6.6 Sources 33


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Table 3: Detailed TNM Classification 14
Table 4: Drug Risk Benefit Score of Vargatef 18
Table 5: Annual Cost of Therapy of Vargatef, 2017 20
Table 6: Vargatef, Ovarian Cancer, Global, Sales Forecasts ($m), 20172020 21
Table 7: Vargatef, Ovarian Cancer, The US, Sales Forecasts ($m), 20172020 22
Table 8: Vargatef, Ovarian Cancer, The UK, Sales Forecasts ($m), 20172020 23
Table 9: Vargatef, Ovarian Cancer, France, Sales Forecasts ($m), 20172020 24
Table 10: Vargatef, Ovarian Cancer, Germany, Sales Forecasts ($m), 20172020 25
Table 11: Vargatef, Ovarian Cancer, Italy, Sales Forecasts ($m), 20172020 26
Table 12: Vargatef, Ovarian Cancer, Spain, Sales Forecasts ($m), 20172020 27


Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 10
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 11
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 11
Figure 6: Broad Classification of Ovarian Cancer 13
Figure 7: Classification of Ovarian Cancer 15
Figure 8: Drug Model Diagram of Vargatef 19
Figure 9: Vargatef, Ovarian Cancer, Global, Sales Forecasts ($m), 20172020 21
Figure 10: Vargatef, Ovarian Cancer, The US, Sales Forecasts ($m), 20172020 22
Figure 11: Vargatef, Ovarian Cancer, The UK, Sales Forecasts ($m), 20172020 23
Figure 12: Vargatef, Ovarian Cancer, France, Sales Forecasts ($m), 20172020 24
Figure 13: Vargatef, Ovarian Cancer, Germany, Sales Forecasts ($m), 20172020 25
Figure 14: Vargatef, Ovarian Cancer, Italy, Sales Forecasts ($m), 20172020 26
Figure 15: Vargatef, Ovarian Cancer, Spain, Sales Forecasts ($m), 20172020 27
Figure 16: Vargatef, Ovarian Cancer, Global, Sales Distribution by Country (%), 2020 28
Figure 17: Drug Model Diagram 31
Figure 18: Patients Approved for the Drug 31